...Ian Marpuri; Mitchell E. Geffner; Lily C. Chao Introduction: Histrelin acetate implant (HI) is an approved treatment option for children with central precocious puberty. Implant duration has been reported to surpass the recommended replacement interval of 1–2 years. Implant breakage is a known...

... of central precocious puberty (CPP) is increasing. Recent evidence demonstrates that obesity and high-fat diets induce inflammation in the mediobasal hypothalamus in humans, a region housing both the primary appetite-regulating centers and the GnRH neurons. Early activation of GnRH neurons is implicated...

... with central precocious puberty (CPP) are located in the coding regions of MKRN3 or DLK1 genes. Notably, potential abnormalities in the regulatory regions of these CPP genes are rarely explored. The objective of this work was to identify pathogenic allelic variants in the regulatory regions of MKRN3 and DLK1...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 DLK1 Central precocious puberty Familial central precocious puberty Metabolism Welcome Trust Established Facts Loss-of-function sequence...

...Karen O. Klein; Bradley S. Miller; Nelly Mauras Introduction: Phase 3 trial of 6-month subcutaneous leuprolide acetate (SC-LA) in children with central precocious puberty (CPP) demonstrated efficacy and safety. The aims of this secondary analysis were to evaluate unstimulated luteinizing hormone...

...Lawrence A. Silverman; Mitchell E. Geffner; Matthew Benson Introduction: Studies of gonadotropin-releasing hormone analogues (intramuscular [IM] leuprolide acetate [LA] and triptorelin) for treatment monitoring of central precocious puberty (CPP) demonstrate this approach is effective...

...Ling Hou; Yanqin Ying; Wei Wu; Feng Ye; Cai Zhang; Xiaoping Luo Background: Recently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment...

... and 4.3%. It remains controversial whether women with a history of idiopathic central precocious puberty (ICPP) are at increased risk for PCOS. Our objective was to assess the prevalence of PCOS in adolescents with a history of ICPP compared with healthy adolescents and the prevalence of PCOS among ICPP...

...Jennifer Ni; Carolyn Chi; Tandy Aye Background: Gonadotrophin-releasing hormone agonists (GnRHas) are used for puberty suppression in central precocious puberty (CPP) and gender dysphoria (GD). Guidelines on biochemical monitoring are not defined. Objectives: The aim of this study was to evaluate...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Central precocious puberty Testosterone Estradiol GnRH analog The youngest documented case of central precocious puberty (CPP) was that of a Peruvian girl named Lina Marcela Medina de Jurado...

... gonadotropin-releasing hormone (GnRH) signalling and that the addition of a protease inhibitor to sampling tubes preserves the AG levels. Methods: In this randomized, placebo-controlled, cross-over study, 13 girls with suspected central precocious puberty were included. They performed an adjusted GnRH...

... of gonadotropin response to gonadotropin-releasing hormone analogs (GnRHas) corresponding to the activation of the hypothalamic-pituitary-gonadal axis that could differentiate central precocious puberty (CPP) from premature thelarche (PT) and using the electrochemiluminescence assay method. Methods: A total of 49...

...Patricia Diaz Escagedo; Cheri L. Deal; Andrew A. Dwyer; Michael Hauschild Background: Central precocious puberty (CPP) in females is characterized by thelarche before 8 years of age. Evidence of reproductive axis activation confirms the diagnosis (basal serum luteinizing hormone (LH) ≥0.3 IU/L...

... effect on gonadotropins secretion [ 21, 51-55 ]. The datasets used in this study are available from the corresponding author on reasonable request. References 1. Latronico   AC , Brito   VN , Carel   JC . Causes, diagnosis, and treatment of central precocious puberty . Lancet...

...Lauren A. Logan; Erica A. Eugster Background: A random ultrasensitive luteinizing hormone (LH) (LH-ICMA) ≥0.3 mIU/L is highly accurate in confirming a diagnosis of central precocious puberty (CPP). However, a prepubertal value does not exclude the diagnosis. The clinical differences between...

... Central precocious puberty Nonclassical congenital adrenal hyperplasia Low-value care Premature thelarche (PT) and premature adrenarche (PA) are the 2 most common variations of early pubertal development seen by pediatric endocrinologists. Typical cases are usually easy to recognize based...

... on our experience. Patients and Methods: Nine of 232 (3.8%) patients with central precocious puberty receiving GnRH analogue treatment had systemic hypersensitivity reactions in 4 years’ period. Six patients had a type 1 hypersensitivity reaction (generalized hives, pruritus, and/or edema) to triptorelin...

...Anna Grandone; Grazia Cirillo; Marcella Sasso; Gianluca Tornese; Caterina Luongo; Adalgisa Festa; Pierluigi Marzuillo; Emanuele Miraglia del Giudice Background: Recently, mutations of makorin RING finger protein 3 ( MKRN3 ) have been identified in familial central precocious puberty (CPP). Serum...

...Paul B. Kaplowitz; Philippe F. Backeljauw; David B. Allen The use of gonadotropin-releasing hormone analogs (GnRHa) for the treatment of central precocious puberty (CPP), especially in girls, has increased rapidly in recent years. In the context of a secular trend towards earlier puberty onset...

...Melissa J. Schoelwer; Kelly L. Donahue; Paula Didrick; Erica A. Eugster Background: To determine whether psychological characteristics of girls with variations of early puberty and their mothers change over time and with treatment in girls with central precocious puberty (CPP). Methods: Girls...